title: Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
abstract: OBJECTIVE
  To evaluate the long-term effectiveness and late toxicities of paclitaxel (PTX) plus cisplatin (DDP) with concurrent radiotherapy for locally advanced esophageal squamous cancer.
  
  
  METHODS
  Between 2008 and 2011, 76 patients were enrolled in a phase II study on the treatment of loco-regionally advanced esophageal cancer with radiotherapy (68.4 Gy/44 fractions or 61.2 Gy/34 fractions) combined with 4-cycle chemotherapy consisting of DDP (25 mg/m2per day for 3 d) and PTX (175 mg/m2for 3 h). The primary endpoints were overall survival and progression-free survival, and the secondary endpoints were toxicity and the treatment failure pattern.
  
  
  RESULTS
  A total of 76 patients were enrolled in this study, of whom 63.2% finished the whole regimen. The 5-year survival rates for the per-protocol population and intent-to-treat population were 25.4% and 26.4%, respectively, and the median survival rates were 23.7 mo and 28.5 mo, respectively. Grade 3 or 4 late toxicity was observed in only one patient (heart failure). In log-rank analysis, the pretreatment stage (stage II + III: 36.1 movsstage IV: 14.9 mo) and the completed cycle (1-3 cycles: 16.1 movs4 cycles: 35.5 mo) were significant prognostic factors (P= 0.037 < 0.05 andP= 0.013 < 0.05).
  
  
  CONCLUSIONS
  Radiotherapy combined with chemotherapy consisting of PTX and DDP is a safe and effective definitive treatment for loco-regionally advanced esophageal squamous cancer.
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Han-Ting
authors.initials: HT
authors.lastname: Zhu
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Da-Shan
authors.initials: DS
authors.lastname: Ai
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Hua-Rong
authors.initials: HR
authors.lastname: Tang
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Harun
authors.initials: H
authors.lastname: Badakhshi
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Jian-Hong
authors.initials: JH
authors.lastname: Fan
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Jia-Ying
authors.initials: JY
authors.lastname: Deng
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Jun-Hua
authors.initials: JH
authors.lastname: Zhang
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Xia
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Xiao-Mao
authors.initials: XM
authors.lastname: Guo
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Jiang
authors.affiliation: Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Kuai-Le
authors.initials: KL
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D004938:Esophageal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel; D002945:Cisplatin
keywords: Chemoradiotherapy; Loco-regionally advanced esophageal cancer; Long-term result; Phase II trial